Published in Vascul Pharmacol on June 29, 2012
Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases. Genomics Inform (2013) 0.94
Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease. Vascul Pharmacol (2015) 0.91
Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Invest (2014) 0.84
Present and future in the treatment of diabetic kidney disease. J Diabetes Res (2015) 0.84
Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice. Diabetologia (2015) 0.83
Methylglyoxal induces mitochondrial dysfunction and cell death in liver. Toxicol Res (2014) 0.82
Vitamin D status is associated with skin autofluorescence in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol (2015) 0.79
Induction of endothelial RAGE expression in pterygium. Mol Vis (2014) 0.79
Role of receptor for advanced glycation end products (RAGE) in liver disease. Eur J Med Res (2015) 0.78
The multiple faces of RAGE - opportunities for therapeutic intervention in aging and chronic disease. Expert Opin Ther Targets (2015) 0.78
Effects of methanolic extracts from edible plants on endogenous secretory receptor for advanced glycation end products induced by the high glucose incubation in human endothelial cells. J Pharm Bioallied Sci (2015) 0.77
GeneOptimizer program-assisted cDNA reengineering enhances sRAGE autologous expression in Chinese hamster ovary cells. Protein Expr Purif (2013) 0.77
Decreased circulatory response to hypovolemic stress in young women with type 1 diabetes. Diabetes Care (2013) 0.77
Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction. Sci Rep (2016) 0.76
Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients. BMC Endocr Disord (2013) 0.76
Huang Gan Formula Eliminates the Oxidative Stress Effects of Advanced Oxidation Protein Products on the Divergent Regulation of the Expression of AGEs Receptors via the JAK2/STAT3 Pathway. Evid Based Complement Alternat Med (2017) 0.75
The AGE-RAGE Axis and Its Relationship to Markers of Cardiovascular Disease in Newly Diagnosed Diabetic Patients. PLoS One (2016) 0.75
Ligature-associated bacterial profiles are linked to type 2 diabetes mellitus in a rat model and influenced by antibody treatment against TNF-α or RAGE. Clin Exp Dent Res (2017) 0.75
AGEs induce ectopic endochondral ossification in intervertebral discs Eur Cell Mater (2016) 0.75
Reduced Venous Compliance in Young Women with Type 1 Diabetes - Further Aggravated by Prolonged Elevated Levels of HbA1c. Front Endocrinol (Lausanne) (2016) 0.75
Steap4 attenuates high glucose and S100B-induced effects in mesangial cells. J Cell Mol Med (2015) 0.75
Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients. PLoS One (2017) 0.75
Ameliorative Effects of Nilotinib on CCl4 Induced Liver Fibrosis Via Attenuation of RAGE/HMGB1 Gene Expression and Oxidative Stress in Rat. Chonnam Med J (2017) 0.75
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med (2003) 5.87
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA (2010) 4.41
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem (1992) 3.64
Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem (1999) 3.12
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med (2003) 2.94
The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J (1990) 2.83
Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol (2004) 2.54
Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem (1997) 2.53
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol (2007) 2.29
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res (2010) 2.19
Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest (1993) 1.99
Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest (2005) 1.97
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol (2005) 1.95
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res (2008) 1.94
Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol (2000) 1.92
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med (2007) 1.88
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol (2003) 1.85
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ Res (2010) 1.73
The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.55
Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J Biol Chem (2002) 1.46
Retracted Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes (2007) 1.44
RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes (2006) 1.43
Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci (2005) 1.41
Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem (2001) 1.39
Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes (2011) 1.35
Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes (2010) 1.32
Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes (1992) 1.32
Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis (2006) 1.31
Type 2 diabetes: an epidemic requiring global attention and urgent action. Diabetes Care (2012) 1.29
Soluble forms of RAGE in internal medicine. Intern Emerg Med (2009) 1.28
Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes (1995) 1.25
Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab (2004) 1.25
AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep (2011) 1.23
Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res (2010) 1.22
Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem (2000) 1.20
Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med (2009) 1.19
Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress. Mol Cell Biochem (2009) 1.19
RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes (2008) 1.18
Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol (2002) 1.18
Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem (1995) 1.15
RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways. PLoS One (2010) 1.15
High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis (2011) 1.10
Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci (2005) 1.08
Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem (2010) 1.06
Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J Clin Invest (2012) 1.06
Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem (2011) 1.04
Loss of RAGE defense: a cause of Charcot neuroarthropathy? Diabetes Care (2011) 1.02
Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. Circ Res (2012) 0.96
Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol (2009) 0.96
Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism (1998) 0.95
Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression. Eur J Clin Invest (2011) 0.90
Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Eur J Endocrinol (2011) 0.89
Opposing roles of RAGE and Myd88 signaling in extensive liver resection. FASEB J (2011) 0.89
Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail (2009) 0.88
sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res (2007) 0.86
Morphological Changes and Immunohistochemical Expression of RAGE and its Ligands in the Sciatic Nerve of Hyperglycemic Pig (Sus Scrofa). Biochem Insights (2010) 0.84
Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. J Investig Med (2011) 0.81
The expression and down stream effect of lectin like-oxidized low density lipoprotein 1 (LOX-1) in hyperglycemic state. Acta Med Indones (2007) 0.79
The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents. Clin Hemorheol Microcirc (2010) 0.77
Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients. Metabolism (2009) 0.77
Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation (2006) 5.31
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res (2004) 4.00
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 3.93
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology (2005) 2.74
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res (2003) 2.25
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res (2010) 2.19
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2003) 2.17
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation (2003) 2.14
Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab (2008) 2.13
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem (2003) 2.05
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
Identification, classification, and expression of RAGE gene splice variants. FASEB J (2007) 1.96
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res (2008) 1.94
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts. J Leukoc Biol (2009) 1.84
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology (2004) 1.77
Protein glycation: a firm link to endothelial cell dysfunction. Circ Res (2004) 1.76
RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis (2005) 1.67
Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci (2008) 1.67
Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med (2003) 1.62
Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci (2011) 1.60
Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg (2009) 1.60
Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J (2013) 1.60
Development of receptor for advanced glycation end products-directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis. Circ Cardiovasc Imaging (2008) 1.58
Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev (2002) 1.56
The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.55
Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol (2004) 1.55
PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice. Arterioscler Thromb Vasc Biol (2013) 1.52
RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) (2009) 1.52
Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) (2009) 1.51
Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation (2006) 1.48
Retracted Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes (2007) 1.44
RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum (2007) 1.44
RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol (2008) 1.41
Imaging of receptors for advanced glycation end products in experimental myocardial ischemia and reperfusion injury. JACC Cardiovasc Imaging (2012) 1.40
Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol (2005) 1.39
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med (2007) 1.38
Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation (2003) 1.38
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol (2006) 1.38
Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev (2002) 1.37
Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol (2007) 1.36
Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol Nutr Food Res (2007) 1.35
RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J (2004) 1.35
RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med (2005) 1.35
The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med (2009) 1.35
AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol (2008) 1.32
Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes (2010) 1.32
Mechanisms for the induction of HNE- MDA- and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res (2005) 1.31
Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep (2002) 1.30
Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol (2003) 1.30
RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol (2008) 1.29
At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol (2005) 1.27
Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. Circ Res (2003) 1.27
Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J Immunol (2007) 1.26
RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol (2002) 1.25
Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med (2009) 1.25
RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol (2008) 1.24
Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J (2009) 1.23
Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res (2010) 1.22
Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol (2010) 1.22
Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. Diabetes Care (2005) 1.19
Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J (2004) 1.19
RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes (2008) 1.18
Antagonism of RAGE suppresses peripheral nerve regeneration. FASEB J (2004) 1.18
Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis (2011) 1.17
Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci (2008) 1.17
The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond. Trends Cardiovasc Med (2005) 1.16